Ligand-independent oncogenic signaling by the epidermal growth factor receptor

v-ErbB as a paradigm

Julie L. Boerner, Andrew Danielsen, Nita J. Maihle

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

Relay of information from the extracellular environment into the cell often results from a peptide growth factor binding to its cognate cell surface receptor; this event is an integral mechanism by which many cellular functions occur, including cell growth, motility, and survival. In recent years, however, this requirement for ligand binding has been shown to be surpassed by several distinct mechanisms, including cell surface receptor cross-talk (e.g., between epidermal growth factor receptor [EGFR] and G-coupled receptors), receptor-extracellular matrix interactions (e.g., EGFR: integrin complexes), and finally by structural mutations within the receptor itself. While all of these pathways result in so-called ligand-independent signaling by the EGF receptor, to date, only structural mutations in the receptor have been shown to result in qualitative changes in downstream targets of the receptor, which specifically result in oncogenic signaling, transformation, and tumorigenicity. In this review, we describe aspects of the known signaling properties of the retroviral oncogene v-ErbB as a model of ligand-independent oncogenic signaling, and compare these properties to results emerging from ongoing studies on structurally related EGF receptor mutants originally identified in human tumors. A better understanding of the signaling pathways used by these uniquely oncogenic receptor tyrosine kinase mutants may ultimately reveal new targets for the development of novel therapeutics selective for the inhibition of tumor cell growth.

Original languageEnglish (US)
Pages (from-to)111-121
Number of pages11
JournalExperimental Cell Research
Volume284
Issue number1
DOIs
StatePublished - Mar 10 2003
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Ligands
Cell Surface Receptors
Receptor Cross-Talk
erbB-1 Genes
Mutation
Receptor Protein-Tyrosine Kinases
Growth
Integrins
Cell Movement
Neoplasms
Cell Survival
Intercellular Signaling Peptides and Proteins
Peptides
Therapeutics

Keywords

  • Caldesmon
  • Cancer
  • EGF receptor
  • ErbB
  • Ligand-independent signaling
  • Oncogenes
  • Oncogenic signaling
  • Pak
  • Receptor tyrosine kinase
  • v-ErbB

ASJC Scopus subject areas

  • Cell Biology

Cite this

Ligand-independent oncogenic signaling by the epidermal growth factor receptor : v-ErbB as a paradigm. / Boerner, Julie L.; Danielsen, Andrew; Maihle, Nita J.

In: Experimental Cell Research, Vol. 284, No. 1, 10.03.2003, p. 111-121.

Research output: Contribution to journalReview article

Boerner, Julie L. ; Danielsen, Andrew ; Maihle, Nita J. / Ligand-independent oncogenic signaling by the epidermal growth factor receptor : v-ErbB as a paradigm. In: Experimental Cell Research. 2003 ; Vol. 284, No. 1. pp. 111-121.
@article{063a125600744218a2eadee34359b67b,
title = "Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm",
abstract = "Relay of information from the extracellular environment into the cell often results from a peptide growth factor binding to its cognate cell surface receptor; this event is an integral mechanism by which many cellular functions occur, including cell growth, motility, and survival. In recent years, however, this requirement for ligand binding has been shown to be surpassed by several distinct mechanisms, including cell surface receptor cross-talk (e.g., between epidermal growth factor receptor [EGFR] and G-coupled receptors), receptor-extracellular matrix interactions (e.g., EGFR: integrin complexes), and finally by structural mutations within the receptor itself. While all of these pathways result in so-called ligand-independent signaling by the EGF receptor, to date, only structural mutations in the receptor have been shown to result in qualitative changes in downstream targets of the receptor, which specifically result in oncogenic signaling, transformation, and tumorigenicity. In this review, we describe aspects of the known signaling properties of the retroviral oncogene v-ErbB as a model of ligand-independent oncogenic signaling, and compare these properties to results emerging from ongoing studies on structurally related EGF receptor mutants originally identified in human tumors. A better understanding of the signaling pathways used by these uniquely oncogenic receptor tyrosine kinase mutants may ultimately reveal new targets for the development of novel therapeutics selective for the inhibition of tumor cell growth.",
keywords = "Caldesmon, Cancer, EGF receptor, ErbB, Ligand-independent signaling, Oncogenes, Oncogenic signaling, Pak, Receptor tyrosine kinase, v-ErbB",
author = "Boerner, {Julie L.} and Andrew Danielsen and Maihle, {Nita J.}",
year = "2003",
month = "3",
day = "10",
doi = "10.1016/S0014-4827(02)00096-4",
language = "English (US)",
volume = "284",
pages = "111--121",
journal = "Experimental Cell Research",
issn = "0014-4827",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Ligand-independent oncogenic signaling by the epidermal growth factor receptor

T2 - v-ErbB as a paradigm

AU - Boerner, Julie L.

AU - Danielsen, Andrew

AU - Maihle, Nita J.

PY - 2003/3/10

Y1 - 2003/3/10

N2 - Relay of information from the extracellular environment into the cell often results from a peptide growth factor binding to its cognate cell surface receptor; this event is an integral mechanism by which many cellular functions occur, including cell growth, motility, and survival. In recent years, however, this requirement for ligand binding has been shown to be surpassed by several distinct mechanisms, including cell surface receptor cross-talk (e.g., between epidermal growth factor receptor [EGFR] and G-coupled receptors), receptor-extracellular matrix interactions (e.g., EGFR: integrin complexes), and finally by structural mutations within the receptor itself. While all of these pathways result in so-called ligand-independent signaling by the EGF receptor, to date, only structural mutations in the receptor have been shown to result in qualitative changes in downstream targets of the receptor, which specifically result in oncogenic signaling, transformation, and tumorigenicity. In this review, we describe aspects of the known signaling properties of the retroviral oncogene v-ErbB as a model of ligand-independent oncogenic signaling, and compare these properties to results emerging from ongoing studies on structurally related EGF receptor mutants originally identified in human tumors. A better understanding of the signaling pathways used by these uniquely oncogenic receptor tyrosine kinase mutants may ultimately reveal new targets for the development of novel therapeutics selective for the inhibition of tumor cell growth.

AB - Relay of information from the extracellular environment into the cell often results from a peptide growth factor binding to its cognate cell surface receptor; this event is an integral mechanism by which many cellular functions occur, including cell growth, motility, and survival. In recent years, however, this requirement for ligand binding has been shown to be surpassed by several distinct mechanisms, including cell surface receptor cross-talk (e.g., between epidermal growth factor receptor [EGFR] and G-coupled receptors), receptor-extracellular matrix interactions (e.g., EGFR: integrin complexes), and finally by structural mutations within the receptor itself. While all of these pathways result in so-called ligand-independent signaling by the EGF receptor, to date, only structural mutations in the receptor have been shown to result in qualitative changes in downstream targets of the receptor, which specifically result in oncogenic signaling, transformation, and tumorigenicity. In this review, we describe aspects of the known signaling properties of the retroviral oncogene v-ErbB as a model of ligand-independent oncogenic signaling, and compare these properties to results emerging from ongoing studies on structurally related EGF receptor mutants originally identified in human tumors. A better understanding of the signaling pathways used by these uniquely oncogenic receptor tyrosine kinase mutants may ultimately reveal new targets for the development of novel therapeutics selective for the inhibition of tumor cell growth.

KW - Caldesmon

KW - Cancer

KW - EGF receptor

KW - ErbB

KW - Ligand-independent signaling

KW - Oncogenes

KW - Oncogenic signaling

KW - Pak

KW - Receptor tyrosine kinase

KW - v-ErbB

UR - http://www.scopus.com/inward/record.url?scp=0037429728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037429728&partnerID=8YFLogxK

U2 - 10.1016/S0014-4827(02)00096-4

DO - 10.1016/S0014-4827(02)00096-4

M3 - Review article

VL - 284

SP - 111

EP - 121

JO - Experimental Cell Research

JF - Experimental Cell Research

SN - 0014-4827

IS - 1

ER -